Purpose of review Uterine fibroids are extremely common, and can cause significant morbidity, yet the exact cause of these tumors remains elusive and there are currently no long-term treatments available. In this review, we aim to provide an overview of steroid hormones, genetic abnormalities, and stem cells in the pathogenesis of uterine fibroids.
INTRODUCTION
Uterine fibroids occur in up to 80% of reproductiveage women, causing significant morbidity in up to 30% of women [1] [2] [3] [4] . In the United States, more than 200 000 surgical procedures are performed for the treatment of fibroids, with yearly cost estimates of $5.9À34.4 billion [5] . Despite this impressive prevalence, the exact cause of uterine fibroids remains elusive and there are currently no long-term treatments available. Studies have suggested that fibroids are monoclonal tumors developed from a single myocyte [6, 7] , but the inciting event for neoplastic transformation of a myocyte is currently unknown. Tumor growth is characterized by slow proliferation with concurrent deposition of abundant extracellular matrix ( Fig. 1) , usually in a steroid-hormone-dependent manner [8, 9] . This review provides an overview of the current state of knowledge on the role of steroid hormones in fibroid development, treatments targeting steroid hormone action, and the more recent discoveries regarding genetic abnormalities and stem cells in the pathogenesis of uterine fibroids.
Estrogen receptor-a is a more potent activator of transcription and is thought to be regulated by estrogen receptor-b, although much remains unknown about the exact roles of the two receptors and their interactions [16] . Additionally, there have now been several studies that have reported specific estrogen receptor-a polymorphisms that increase susceptibility to uterine fibroids [17, 18] .
Fibroids respond to estrogen in the bloodstream as a result of ovarian steroidogenesis, and also produce estrogen in situ through local conversion of androgens by aromatase [19] . Fibroids have been shown to have higher estrogen levels than adjacent myometrium, and correspondingly increased aromatase and 17b-hydroxysteroid dehydrogenase-type 1 levels [19] [20] [21] [22] . Interestingly, aromatase RNA is not found in the myometrium of women without fibroids [19] . The addition of androstenedione alone to cultured fibroid cells leads to estradiol production, with resultant cellular proliferation comparable to that caused by the addition of estradiol alone, suggesting that fibroids are capable of producing sufficient estrogen to sustain their own growth [21] . The addition of aromatase inhibitors to fibroid cell culture reverses this effect [21] .
Progesterone
In addition to estrogen and aromatase, there is accumulating evidence that progesterone plays a critical role in uterine fibroid expansion [23] and is essential for estrogen-related fibroid growth
KEY POINTS
A universal feature of fibroids is responsiveness to estrogen and progesterone.
Ulipristal could be the first long-term treatment for uterine fibroids.
Fibroids contain somatic stem cells that are necessary for growth, but require paracrine signals from surrounding mature cells.
Genetic mutations, particularly those affecting MED12 and HMGA2, likely explain some fibroid pathogenesis.
Targeting the products of genetic mutations or fibroid stem cells has the potential to achieve both better control of current tumors and the prevention of the development of new fibroids. [ [24] [25] [26] [27] [28] . Progesterone acts through two isoforms of progesterone, progesterone-A and progesterone-B, both of which exhibit higher expression in fibroids compared with adjacent myometrium [29] [30] [31] . Similar to estrogen receptor, relatively little is known about the specific roles and interplay of progesterone-A and progesterone-B in fibroids.
In support of a key role for progesterone, markers of proliferation and mitotic counts are the highest in fibroid tissue during the luteal phase [25, 28] , and fibroid proliferative activity in postmenopausal women has been shown to increase significantly with combined estrogen and progestin replacement but not with estrogen replacement alone [25] . In a xenograft mouse model, Ishikawa et al. [26] showed that estrogen regulates expression of progesterone via estrogen receptor-a, and progesterone directly stimulates fibroid growth. In this model, estrogen with progesterone stimulated both fibroid cell proliferation and extracellular matrix formation, and these effects were abolished by cotreatment with a progesterone receptor antagonist [26] . These findings suggest a more permissive role for estrogen, allowing fibroid responsiveness to progesterone via induction of progesterone [4, 26] .
Recently, in a xenograft model, Qiang et al. [32 & ] demonstrated that treatment with estrogen and progesterone resulted in the formation of extracellular matrix production via downregulation of miR-29b. Gene expression of miR-29b has been consistently shown to be lower in fibroid tissues compared with adjacent normal myometrium tissues, both in vitro and in vivo [32 & ,33,34] and increasing mir-29b levels in fibroid cells with mir-29b lentivirus decreased levels of collagen 1a1 [32 & ]. Lastly, estrogen with progesterone, but not estrogen alone, decreased miR-29b expression, suggesting a role for progesterone in promoting uterine fibroid growth via miR29n downregulation [32 & ].
MEDICAL TREATMENTS
Although the mainstay of fibroid treatment has traditionally been surgical, much recent research has focused on less invasive medical therapies. Historically, gonadotropin releasing hormone (GnRH) agonists were first-line therapy for fibroids, but they can cause severe menopausal symptoms, and cannot be used long term. A number of reviews are available on nonsurgical management of fibroids [35,36 & ,37-39] , so the topic will not be reviewed in depth here. Currently available therapies are summarized in Table 1 [35,36 & ,39] . As proofof-principle of the above-mentioned hormonal aspects, we will briefly review the aromatase inhibitors and selective progesterone receptor modulators (SPRMs), highlighting the exciting recent progress with ulipristal acetate.
Aromatase inhibitors
Because aromatase is thought to play such a critical role in estrogen production in fibroids, aromatase inhibitors are a logical treatment choice. Nonsteroidal aromatase inhibitors reversibly bind the aromatase enzyme, decreasing binding by androstenedione or testosterone and thus decreasing conversion to estradiol [40, 41] . Although the original aromatase inhibitors were relatively nonselective and fraught with side-effects, third-generation aromatase inhibitors are more selective and have superior bioavailability and side-effect profiles. Anastrozole and letrozole are able to inhibit more than 98% of aromatase activity [40, 42] , and have been shown to result in significant reduction of fibroid volume and improvement in symptoms in multiple clinical trials [43] [44] [45] [46] . Moreover, aromatase inhibitors avoid the side-effects of the severe hypoestrogenism caused by GnRH agonists, particularly hot flushes [44] .
Although most women tolerate aromatase inhibitors relatively well, there are potential sideeffects. The most commonly reported side-effects include hot flashes and musculoskeletal pain. Importantly, aromatase inhibitors are often used off-label in the follicular phase for ovulation induction or controlled ovarian stimulation, necessitating contraception in women not desiring conception [47] . Although there have been conflicting results regarding the potential for systemic hypoestrogenism with prolonged aromatase inhibitor use [44, 48] , there is concern for both increased bone loss and cardiovascular risk with long-term aromatase inhibitor use, particularly in younger patients [42] . The breast cancer literature has also brought some questions as to the utility of aromatase inhibitors, reporting both decreased effectiveness in overweight and obese women and the development of resistance over time [40, 42] . Additionally, the effects of aromatase inhibitors are only temporary, and fibroids regrow with cessation of treatment, albeit to smaller volumes [44] . Taken together, the current evidence suggests that aromatase inhibitors are, at best, a short-term solution in selected populations of women.
Selective progesterone receptor modulators
All of the SPRMs that have been studied in clinical trials -mifepristone (RU486), asoprisnil (J867), ulipristal acetate (CDB2914), and telapristone acetate (CDB4124) -have been shown to reduce fibroid size 
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and improve quality of life [49] [50] [51] . In vitro, fibroid cells treated with ulipristal acetate, telapristone acetate, or asoprisnil exhibit decreased cell proliferation and increased apoptosis [52] [53] [54] [55] [56] . Moreover, asoprisnil and ulipristal both decrease extracellular matrix formation [55, 57, 58] . These effects are not seen with the treatment of myometrial cells, suggesting tissue specificity of these drugs. Both asoprisnil and ulipristal acetate also have high affinity for progesterone [59, 60] , suggesting that the genomewide binding status of progesterone liganded with ulipristal or asoprisnil should be further investigated.
Most recent research has focused on ulipristal acetate. Although the Food and Drug Administration has not yet approved ulipristal acetate for indications beyond contraception in the United States, it has been approved in both Canada and Europe for the treatment of fibroids. Clinical trials have shown that, while GnRH agonist causes greater overall reduction in fibroid volume, ulipristal acetate has longer lasting effects after cessation of treatment [8, 50, 61, 62] . Additionally, ulipristal acetate results in a lower incidence of hot flashes, impact on bone density, and suppression of E 2 levels when compared with GnRH agonist [62, 63] . Moreover, Donnez et al. [64 & ] recently reported that repeated 3-month courses of ulipristal resulted in amenorrhea in almost 90% of women and was well tolerated [65 && ]. This exciting study suggests that ulipristal could be the first long-term treatment for uterine fibroids.
Because SPRMs block progesterone action in the endometrium, concern has been raised that they may result in endometrial thickening and premalignant or malignant transformation. There are now studies showing that treatment with SPRMs does not appear to result in increased mitosis or atypia; however, asymmetry of stromal and epithelial growth and cystic, dilated glands have been reported, and are now classified as progesterone receptor modulatorassociated endometrial change (PAEC) [49, 66, 67 ]. Encouragingly, one study observed reversal of these changes and return to normal endometrial histology 6 months after ulipristal acetate discontinuation [67] , and the study of repeated courses of ulipristal did not report any increase in PAEC or other histological changes [65 && ], but longer term studies are needed to definitively understand the risks and side-effects of SPRMs.
SOMATIC STEM CELLS
Somatic stem cells were first discovered in myometrial tissues, in which they are capable of both selfrenewal and the production of tissue-specific daughter cells under the influence of estrogen and progesterone [68] [69] [70] . More recently, small populations of fibroid cells consistent with somatic stem cells have also been isolated [71, 72] . Despite the fact that fibroids contain lesser stem cells than the myometrium [73] , there is evidence that the fibroid stem cell population is essential for steroid hormonedependent fibroid growth [71, 72] . In a mouse xenograft model, injected cell suspensions containing fibroid stem cells mixed with myometrial cells grew into substantially bigger tumors and had higher proliferation indices under the influence of estrogen and progesterone than injected suspensions containing only differentiated fibroid cells with myometrial cells [72] . Perhaps most interestingly, fibroid stem cells have minimal to no estrogen receptor and progesterone expression, yet respond to estrogen and progesterone stimulation with tumor expansion. Additionally, fibroid stem cells cannot induce proliferation or tumor growth without the presence of differentiated fibroid or myometrial cells. These observations have led us to hypothesize that fibroid stem cells rely on paracrine signaling from surrounding mature myometrial and fibroid cells to facilitate estrogen and progesterone action [72] .
The wingless-type (WNT)/b-catenin pathway was recently proposed by Ono et al. [74] as a possible mechanism for paracrine interaction between fibroid stem and differentiated cells. In that study, mature myometrial cells secreted WNT ligands in response to estrogen and progesterone treatment, resulting in nuclear translocation of b-catenin in proximal fibroid stem cells. Intranuclear b-catenin increased expression of genes involved in growth and proliferation. Additionally, inhibiting WNT binding or b-catenin in fibroid stem cells resulted in significantly decreased tumor growth -an effect not seen in mature fibroid cells [74] .
Much remains to be explored in fibroid stem cells. Originally, fibroid stem cells were isolated using the Hoechst dye exclusion technique for side populations [75, 76] ; however, the side population technique is expensive, exhibits significant sensitivity to minor staining variations, and is detrimental to cell survival, making further study of fibroid cells difficult [77] . As a solution to these pitfalls, we recently reported a novel way of isolating fibroid stem cells using cell surface markers CD34 and CD49b [78 && ]. Cell sorting using antibodies to these cell surface proteins revealed three distinct cell populations: CD34þ/CD49bþ, CD34þ/CD49bÀ, and CD34À/CD49bÀ cells (Fig. 2) . CD34þ/CD49bþ cells were highly enriched with stem cells, whereas the other two groups did not contain any stem cells. Moreover, genes specific to stem cells, such as Kruppel-like factor 4, NANOG and octamer-binding transcription factor 4, were overexpressed in the CD34þ/CD49bþ cells further suggesting that these cells are indeed stem cells [78 && ]. Interestingly, CD34þ/CD49bÀ cells had intermediate levels of these stem cell factors compared with CD34À/ CD49bÀ cells. Additionally, estrogen receptor-a and progesterone were significantly underexpressed in CD34þ/CD49bþ cells, consistent with prior studies on side population, and CD34þ/CD49bÀ cells again showed intermediate expression levels between CD34þ/CD49bþ and CD34À/CD49bÀ cells [78 && ]. Taken together, these results led us to hypothesize that CD34þ/CD49bþ cells are largely fibroid somatic stem cells, capable of asymmetric division allowing both self-renewal and the production of intermediary daughter cells, or CD34þ/ CD49bÀ cells, which ultimately develop into fully differentiated fibroid cells, or CD34À/CD49bÀ cells. An unbiased genome-wide investigation to better characterize the three populations on a molecular level is currently underway and will hopefully lead to new therapeutic targets.
Genetic abnormalities
Recent research suggests that most fibroids fall into one of four categories of mutations: mediator subunit complex 12 (MED12) mutations, fumarate hydratase inactivation, COL4A6-COL4A5 deletions, or high-mobility group AT-hook 2 (HMGA2) overexpression [79,80 & ]. In one study of HMGA2 and MED12 mutations in fibroids, the two mutations appear to be mutually exclusive, raising the possibility that different genetic abnormalities in fibroids actually represent separate pathophysiology [81] . In support of this hypothesis, HMGA2 aberrations are highly correlated with big fibroid tumors, whereas tumors with MED12 mutations tend to be smaller [82, 83] . Because of their possible role in stem cell action, we will focus on HMGA2 and MED12 mutations in this review.
HIGH-MOBILITY GROUP AT-HOOK 2
Mutations involving HMGA2 are found in approximately 7.5% of fibroid tumors and HMGA2 overexpression is due to rearrangements involving chromosome 12q14-15 [83] . In mouse neural stem cells, HMGA2 expression inhibits senescence by downregulating p16 INK4a , a suppressor of stem cell self-renewal [84] . Similarly, HMGA2 has been shown to downregulate p14 Arf, also a negative regulator of self-renewal, in fibroid cells [85] . Finally, uterine fibroids exhibit underexpression of Let-7, which is known to suppress HMGA2 [86] . These findings have led us to hypothesize that the Let7-HMGA2-p14 Arf pathway may play a significant role in fibroid stem cells when altered, resulting in increased selfrenewal and decreased senescence.
MEDIATOR SUBUNIT COMPLEX 12
In the largest study of MED12 mutations in fibroids, specific MED12 mutations were found in 70% of fibroids, although smaller studies have reported a prevalence anywhere from 48 to 92% [80 & ,87]. It has been shown that stem cells from fibroid tissue, but not from myometrial tissue, carry MED12 mutations, supporting our hypothesis that a genetic hit may explain the transformation of a myometrial stem cell to a fibroid stem cell [72] . MED12 regulates Wnt signaling by binding to b-catenin, making it possible that absence of or defects in MED12 in fibroid stem cells could lead to unregulated Wnt/ b-catenin pathway-stimulated tumor growth [4, 88] . Moreover, MED12 deficiency, possibly in somatic stem cells, releases negative regulation of transforming growth factor (TGF)b signaling, resulting in increased proliferation in cancer cells [89, 90] . Taken together, this evidence suggests that MED12 deficiency could lead to activation of the Wnt/bcatenin and TGFb pathway, thereby supporting stem cell renewal, proliferation, and fibrosis in uterine fibroids [4, [90] [91] [92] .
CONCLUSION
Historically, the vast majority of fibroid research has focused on the role of steroid hormones in fibroid Cell sorting by flow cytometry using antibodies to CD34 and CD49b revealed three distinct populations in fibroid cells: CD34þ/CD34þ (þ/þ), CD34þ/CD49bÀ (þ/À), and CD34À/CD49b-(À/À). þ/þ cells had characteristics of somatic stem cells, whereas À/À cells had a well-differentiated phenotype. We hypothesize that þ/À are an intermediate cell type between þ/þ and À/À cells.
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Moravek and Bulun pathogenesis. The result of this work has been the development of medical treatment options targeting steroid hormones, such as GnRH agonists, aromatase inhibitors, and antiprogestins. To date, we have not found a medical treatment for uterine fibroids that results in permanent tumor shrinkage or eradication, or that can be used long term with minimal side-effects, although the data on ulipristal acetate look promising. Finding an effective, longterm treatment for fibroids could have great public health implications, given their high prevalence and associated medical costs. The recent shift in focus from hormones to fibroid stem cells and genetic aberrations should lead not only to a deeper understanding of the specific cause of fibroids, but also to the discovery of new therapeutic targets.
Targeting the products of genetic mutations or fibroid stem cells has the potential to achieve both better control of current tumors and the prevention of the development of new fibroids.
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